Acumen Pharmaceuticals' Alzheimer's Drug Sabirnetug Fails to Meet Primary Endpoint in Phase 2 Trial

Topline results from Acumen Pharmaceuticals' Phase 2 ALTITUDE-AD clinical trial of sabirnetug (ACU193) for early Alzheimer's disease did not meet its primary endpoint of reducing cognitive and functional decline at 18 months. Key secondary endpoints also failed to achieve statistical significance, leading Acumen to cease clinical development of the drug. While sabirnetug was generally well tolerated and showed statistically significant amyloid plaque reduction, these findings did not translate to clinical benefit.